This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBlueprint Medicines（1BPMC）株式概要プレシジョン・セラピー・カンパニーであるブループリント・メディシンズ・コーポレーションは、米国内外でゲノムレベルで定義された癌や血液疾患に対する医薬品を開発している。 詳細1BPMC ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長6/6過去の実績0/6財務の健全性4/6配当金0/6報酬当社が推定した公正価値より68.1%で取引されている 収益は年間60.77%増加すると予測されています リスク分析Italian市場と比較した過去 3 か月間の株価の変動過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見る1BPMC Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€105.1069.4% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-650m1b2016201920222025202620282031Revenue US$1.5bEarnings US$268.4mAdvancedSet Fair ValueView all narrativesBlueprint Medicines Corporation 競合他社PhilogenSymbol: BIT:PHILMarket cap: €936.5mRecordati Industria Chimica e FarmaceuticaSymbol: BIT:RECMarket cap: €10.4bHelyx IndustriesSymbol: BIT:HLXMarket cap: €20.5mHalozyme TherapeuticsSymbol: NasdaqGS:HALOMarket cap: US$8.1b価格と性能株価の高値、安値、推移の概要Blueprint Medicines過去の株価現在の株価US$105.1052週高値US$052週安値US$0ベータ0.901ヶ月の変化-2.41%3ヶ月変化n/a1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化38.62%最新ニュースお知らせ • Jul 18+ 1 more updateBlueprint Medicines Corporation Announces Directorate and Committee ChangesBlueprint Medicines Corporation (the “Company”), on June 2, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with SANOFI, a French soci é t é anonyme (“Parent”), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (“Aventis”), and Rothko Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Aventis (“Purchaser”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Jeffrey W. Albers, Daniella Beckman, Alexis Borisy, Lonnel Coats, Habib Dable, Mark Goldberg, M.D., Kathryn Haviland, Lynn Seely, M.D., and John Tsai, M.D.) resigned from his or her respective position as a member of the Company’s board of directors and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Michael J. Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company.お知らせ • Jul 17Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology IndexBlueprint Medicines Corporation has been dropped from the NASDAQ Biotechnology Index.お知らせ • Jun 13Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesBlueprint Medicines Corporation announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®?/AYVAKYT®? (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM: As previously presented, AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3%) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM: AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM: PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells.お知らせ • Jun 02Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion on June 2, 2025. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Sanofi will pay $344.237175 million for 2.549905 million for Restricted stock units. Sanofi will pay $39.868875 million for 0.295325 million for Performance-based restricted stock units. Sanofi will pay $413.578677 million for 6.925296 million options. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Blueprint common stock representing at least a majority of the outstanding shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Sanofi currently expects to complete the acquisition in the third quarter of 2025. Sanofi plans to finance the transaction with a combination of cash on hand and proceeds from new debt. The tender offer is not subject to any financing condition. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. Upon termination of the Merger Agreement, (i) Sanofi under specified circumstances, including termination following a final order, decree or ruling arising in connection with certain antitrust or foreign investment laws, will be required to pay the Blueprint Medicines a termination fee in the amount of $500 million; and (ii) Blueprint Medicines under specified circumstances, including termination by the Blueprint Medicines to accept and enter into an agreement with respect to a superior proposal, will be required to pay Parent a termination fee in the amount of $318 million. The Company Board unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are advisable and fair to, and in the best interests of, the Company and the holders of the Shares, (ii) adopted the Merger Agreement and approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, and (iii) resolved to recommend that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and the transaction is subject to approval of Blueprint Medicines. Michael J. Aiello; Sachin Kohli of Weil, Gotshal & Manges LLP, Paris served as legal advisor to Sanofi, and Stuart M. Cable, Lisa R. Haddad and James Ding of Goodwin Procter LLP served as legal advisor to Blueprint Medicines. Centerview Partners LLC acted as financial advisor to Blueprint Medicines Corporation.最新情報をもっと見るRecent updatesお知らせ • Jul 18+ 1 more updateBlueprint Medicines Corporation Announces Directorate and Committee ChangesBlueprint Medicines Corporation (the “Company”), on June 2, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with SANOFI, a French soci é t é anonyme (“Parent”), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (“Aventis”), and Rothko Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Aventis (“Purchaser”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Jeffrey W. Albers, Daniella Beckman, Alexis Borisy, Lonnel Coats, Habib Dable, Mark Goldberg, M.D., Kathryn Haviland, Lynn Seely, M.D., and John Tsai, M.D.) resigned from his or her respective position as a member of the Company’s board of directors and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Michael J. Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company.お知らせ • Jul 17Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology IndexBlueprint Medicines Corporation has been dropped from the NASDAQ Biotechnology Index.お知らせ • Jun 13Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesBlueprint Medicines Corporation announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®?/AYVAKYT®? (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM: As previously presented, AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3%) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM: AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM: PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells.お知らせ • Jun 02Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion on June 2, 2025. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Sanofi will pay $344.237175 million for 2.549905 million for Restricted stock units. Sanofi will pay $39.868875 million for 0.295325 million for Performance-based restricted stock units. Sanofi will pay $413.578677 million for 6.925296 million options. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Blueprint common stock representing at least a majority of the outstanding shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Sanofi currently expects to complete the acquisition in the third quarter of 2025. Sanofi plans to finance the transaction with a combination of cash on hand and proceeds from new debt. The tender offer is not subject to any financing condition. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. Upon termination of the Merger Agreement, (i) Sanofi under specified circumstances, including termination following a final order, decree or ruling arising in connection with certain antitrust or foreign investment laws, will be required to pay the Blueprint Medicines a termination fee in the amount of $500 million; and (ii) Blueprint Medicines under specified circumstances, including termination by the Blueprint Medicines to accept and enter into an agreement with respect to a superior proposal, will be required to pay Parent a termination fee in the amount of $318 million. The Company Board unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are advisable and fair to, and in the best interests of, the Company and the holders of the Shares, (ii) adopted the Merger Agreement and approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, and (iii) resolved to recommend that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and the transaction is subject to approval of Blueprint Medicines. Michael J. Aiello; Sachin Kohli of Weil, Gotshal & Manges LLP, Paris served as legal advisor to Sanofi, and Stuart M. Cable, Lisa R. Haddad and James Ding of Goodwin Procter LLP served as legal advisor to Blueprint Medicines. Centerview Partners LLC acted as financial advisor to Blueprint Medicines Corporation.株主還元1BPMCIT BiotechsIT 市場7D0%2.0%0.7%1Yn/a34.2%18.4%株主還元を見る業界別リターン: 1BPMCがItalian Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 1BPMC Italian市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 1BPMC's price volatile compared to industry and market?1BPMC volatility1BPMC Average Weekly Movement7.3%Biotechs Industry Average Movement8.2%Market Average Movement5.3%10% most volatile stocks in IT Market8.7%10% least volatile stocks in IT Market3.3%安定した株価: 1BPMCの株価は、 Italian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間の1BPMCのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2008685Kate Havilandwww.blueprintmedicines.comプレシジョン・セラピー・カンパニーであるブループリント・メディシンズ・コーポレーションは、遺伝子レベルで定義された癌や血液疾患に対する医薬品を米国内外で開発している。同社は、全身性肥満細胞症（SM）および消化管間質腫瘍の治療薬AYVAKIT、低悪性度SMおよびその他の肥満細胞疾患の治療薬として経口投与可能で強力なKIT阻害剤BLU-263を開発している。また、RET融合遺伝子陽性の非小細胞肺癌、甲状腺癌、甲状腺髄様癌の治療薬GAVRETO、上皮成長因子受容体駆動型非小細胞肺癌（NSCLC）の治療薬BLU-945、上皮成長因子受容体遺伝子（EGFR）エクソン20挿入変異を有する患者のNSCLC治療薬BLU-451を開発中である。さらに、進行性骨化性線維異形成症の治療薬としてBLU-782、サイクリンE異常がんの治療薬としてBLU-222、進行がんの治療薬としてBLU-852を開発している。また、クレメンティア・ファーマシューティカルズ社、プロテオバント・セラピューティクス社、CStone Pharmaceuticals社、ジェネンテック社、ホフマン・ラ・ロシュ社、Zai Lab (Shanghai) Co., Ltd.と提携およびライセンス契約を結んでいる。2011年6月に社名をブループリント メディシンズ コーポレーションに変更。ブループリント メディシンズ コーポレーションは2008年に設立され、マサチューセッツ州ケンブリッジに本社を置いている。もっと見るBlueprint Medicines Corporation 基礎のまとめBlueprint Medicines の収益と売上を時価総額と比較するとどうか。1BPMC 基礎統計学時価総額€7.22b収益（TTM）-€134.27m売上高(TTM)€484.66m14.9xP/Sレシオ-53.8xPER（株価収益率1BPMC は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1BPMC 損益計算書（TTM）収益US$562.12m売上原価US$19.77m売上総利益US$542.35mその他の費用US$698.08m収益-US$155.73m直近の収益報告Mar 31, 2025次回決算日該当なし一株当たり利益（EPS）-2.41グロス・マージン96.48%純利益率-27.70%有利子負債／自己資本比率185.4%1BPMC の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/07/17 23:54終値2025/07/17 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Blueprint Medicines Corporation 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関George FarmerBMO Capital Markets Equity ResearchDane LeoneBTIGArlinda LeeCanaccord Genuity7 その他のアナリストを表示
お知らせ • Jul 18+ 1 more updateBlueprint Medicines Corporation Announces Directorate and Committee ChangesBlueprint Medicines Corporation (the “Company”), on June 2, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with SANOFI, a French soci é t é anonyme (“Parent”), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (“Aventis”), and Rothko Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Aventis (“Purchaser”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Jeffrey W. Albers, Daniella Beckman, Alexis Borisy, Lonnel Coats, Habib Dable, Mark Goldberg, M.D., Kathryn Haviland, Lynn Seely, M.D., and John Tsai, M.D.) resigned from his or her respective position as a member of the Company’s board of directors and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Michael J. Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company.
お知らせ • Jul 17Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology IndexBlueprint Medicines Corporation has been dropped from the NASDAQ Biotechnology Index.
お知らせ • Jun 13Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesBlueprint Medicines Corporation announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®?/AYVAKYT®? (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM: As previously presented, AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3%) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM: AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM: PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells.
お知らせ • Jun 02Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion on June 2, 2025. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Sanofi will pay $344.237175 million for 2.549905 million for Restricted stock units. Sanofi will pay $39.868875 million for 0.295325 million for Performance-based restricted stock units. Sanofi will pay $413.578677 million for 6.925296 million options. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Blueprint common stock representing at least a majority of the outstanding shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Sanofi currently expects to complete the acquisition in the third quarter of 2025. Sanofi plans to finance the transaction with a combination of cash on hand and proceeds from new debt. The tender offer is not subject to any financing condition. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. Upon termination of the Merger Agreement, (i) Sanofi under specified circumstances, including termination following a final order, decree or ruling arising in connection with certain antitrust or foreign investment laws, will be required to pay the Blueprint Medicines a termination fee in the amount of $500 million; and (ii) Blueprint Medicines under specified circumstances, including termination by the Blueprint Medicines to accept and enter into an agreement with respect to a superior proposal, will be required to pay Parent a termination fee in the amount of $318 million. The Company Board unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are advisable and fair to, and in the best interests of, the Company and the holders of the Shares, (ii) adopted the Merger Agreement and approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, and (iii) resolved to recommend that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and the transaction is subject to approval of Blueprint Medicines. Michael J. Aiello; Sachin Kohli of Weil, Gotshal & Manges LLP, Paris served as legal advisor to Sanofi, and Stuart M. Cable, Lisa R. Haddad and James Ding of Goodwin Procter LLP served as legal advisor to Blueprint Medicines. Centerview Partners LLC acted as financial advisor to Blueprint Medicines Corporation.
お知らせ • Jul 18+ 1 more updateBlueprint Medicines Corporation Announces Directorate and Committee ChangesBlueprint Medicines Corporation (the “Company”), on June 2, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with SANOFI, a French soci é t é anonyme (“Parent”), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (“Aventis”), and Rothko Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Aventis (“Purchaser”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Jeffrey W. Albers, Daniella Beckman, Alexis Borisy, Lonnel Coats, Habib Dable, Mark Goldberg, M.D., Kathryn Haviland, Lynn Seely, M.D., and John Tsai, M.D.) resigned from his or her respective position as a member of the Company’s board of directors and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Michael J. Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company.
お知らせ • Jul 17Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology IndexBlueprint Medicines Corporation has been dropped from the NASDAQ Biotechnology Index.
お知らせ • Jun 13Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesBlueprint Medicines Corporation announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®?/AYVAKYT®? (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM: As previously presented, AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3%) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM: AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM: PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells.
お知らせ • Jun 02Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion on June 2, 2025. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Sanofi will pay $344.237175 million for 2.549905 million for Restricted stock units. Sanofi will pay $39.868875 million for 0.295325 million for Performance-based restricted stock units. Sanofi will pay $413.578677 million for 6.925296 million options. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Blueprint common stock representing at least a majority of the outstanding shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Sanofi currently expects to complete the acquisition in the third quarter of 2025. Sanofi plans to finance the transaction with a combination of cash on hand and proceeds from new debt. The tender offer is not subject to any financing condition. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. Upon termination of the Merger Agreement, (i) Sanofi under specified circumstances, including termination following a final order, decree or ruling arising in connection with certain antitrust or foreign investment laws, will be required to pay the Blueprint Medicines a termination fee in the amount of $500 million; and (ii) Blueprint Medicines under specified circumstances, including termination by the Blueprint Medicines to accept and enter into an agreement with respect to a superior proposal, will be required to pay Parent a termination fee in the amount of $318 million. The Company Board unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are advisable and fair to, and in the best interests of, the Company and the holders of the Shares, (ii) adopted the Merger Agreement and approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, and (iii) resolved to recommend that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and the transaction is subject to approval of Blueprint Medicines. Michael J. Aiello; Sachin Kohli of Weil, Gotshal & Manges LLP, Paris served as legal advisor to Sanofi, and Stuart M. Cable, Lisa R. Haddad and James Ding of Goodwin Procter LLP served as legal advisor to Blueprint Medicines. Centerview Partners LLC acted as financial advisor to Blueprint Medicines Corporation.
